Radnor, PA – According to filings with the U.S. Securities and Exchange Commission, Mineralys Therapeutics is raising $117,999,994.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jon Congleton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mineralys Therapeutics
Mineralys Therapeutics is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension. We are driven to bring a targeted approach to the management of hypertension. High blood pressure costs the United States $131 billion each year. Controlling hypertension is critical to reducing cardiovascular and renal disease; yet over 50% of hypertension patients fail to achieve control. While the blood pressure goal continues to go down, there have been no innovative treatments for hypertension developed in over ten years. Rather, it has relied on trial, fail and add. This approach leads to polypharmacy, adverse events and poor overall compliance and adherence.

To learn more about Mineralys Therapeutics, visit http://mineralystx.com/

Contact:
Jon Congleton, Chief Executive Officer
888-378-6240
jcongleton@mineralystx.com
https://www.linkedin.com/in/joncongleton/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved